Join the Leqembi group to help and get support from people like you.
Leqembi News
Sense of Life Purpose Lowers Risk for Cognitive Impairment
THURSDAY, Sept. 4, 2025 – A sense of purpose in life (PiL) is associated with a lower risk for and later onset of cognitive impairment, according to a study published online in the October issue of...
A Sense Of Purpose Can Protect Brain Health In Aging
THURSDAY, Aug. 28, 2025 — Having a sense of purpose in life is not only personally fulfilling, but might also protect your brain against the ravages of dementia, a new study says. People who reported ...
Alzheimer’s Drug Leqembi Can Be Safely Administered In Memory Clinics, Study Says
THURSDAY, May 15, 2025 — The 2023 approval of the first drug shown to slow the progression of Alzheimer’s disease came with no small amount of concern from skeptics. Lecanemab (Leqembi) modestly slo...
Lecanemab for Alzheimer Disease Safe, Feasible in Real-World Practice
THURSDAY, May 15, 2025 – Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory clinic, and the frequency of significant adverse events is similar to clinical trials,...
Anti-Amyloid Drug Shows Promise In Preventing Alzheimer's
MONDAY, March 24, 2025 – The best evidence yet that cutting-edge Alzheimer’s disease drugs might indeed ward off the degenerative brain disease has emerged from a small-scale study. An experimental d...
FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., January 27, 2025 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Ch...
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
FRIDAY, Oct. 18, 2024 – Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial sizes, according to a research letter published...
Change in Alzheimer's Drug Vial Size Could Be Big Money-Saver for Medicare
MONDAY, Oct. 14, 2024 – A simple tweak in available vial sizes of the breakthrough Alzheimer’s drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. A...
Alzheimer's Drugs May Work in Whole New Way, Study Finds
THURSDAY, Sept. 11, 2024 – Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration...
FDA Grants Traditional Approval for Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas...
FDA Approves Leqembi (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with Leqembi™ Treatment with Leqembi should be initiated in patients with mild c...